What are the NCCN guidelines for primary induction therapy in patients with multiple myeloma (MM) who are not candidates for transplantation?

Updated: Jul 15, 2019
  • Author: Dhaval Shah, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print
Answer

For primary induction therapy in patients who are not transplant candidates, the NCCN guidelines list the following as preferred regimens [2] :

  • Bortezomib/lenalidomide/dexamethasone (category 1)
  • Lenalidomide/low-dose dexamethasone (category 1)
  • Bortezomib/cyclophosphamide/dexamethasone

Other NCCN-recommended regimens for these cases include the following:

  • Carfilzomib/lenalidomide/dexamethasone
  • Carfilzomib/cyclophosphamide/dexamethasone
  • Ixazomib/lenalidomide/dexamethasone

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!